Kohlmann Johannes, Ferrer Rubén A, Markovic Aleksander, Illes Monica, Kunz Manfred
Klinik für Dermatologie, Venerologie und Allergologie, Universität Leipzig, Philipp-Rosenthal-Str. 23, 04103, Leipzig, Deutschland.
Hautarzt. 2021 Jul;72(7):607-609. doi: 10.1007/s00105-020-04727-8.
A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase‑4 (DPP-4) inhibitor. Diabetes treatment was changed to another genericum of sitagliptin and dapagliflozin. Following our recommendation, sitagliptin was interrupted and monotherapy with dapagliflozin was continued. After 6 weeks, sitagliptin was reassumed due to unsatisfactory diabetes control. Alopecia did not improve. We suspect a connection between DPP‑4 inhibition and development of alopecia due to its immunological potential. We assume that the treatment interruption might have been too short to induce regrowth of hair. DPP‑4 may result in both inhibition and activation of the immune system.
一名64岁男性在使用二甲双胍和二肽基肽酶-4（DPP-4）抑制剂西他列汀治疗1个月后出现全秃。糖尿病治疗方案改为另一种西他列汀和达格列净的通用制剂。按照我们的建议，停用了西他列汀，继续使用达格列净单药治疗。6周后，由于糖尿病控制不佳，重新使用西他列汀。脱发情况并未改善。由于DPP-4具有免疫方面的潜在作用，我们怀疑DPP-4抑制与脱发的发生之间存在关联。我们认为治疗中断时间可能过短，不足以促使头发生长。DPP-4可能对免疫系统既有抑制作用又有激活作用。
